News
HTFL
35.65
+1.92%
0.67
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 2d ago
Weekly Report: what happened at HTFL last week (0615-0619)?
Weekly Report · 4d ago
HeartFlow Shareholders Reelect Directors, Ratify PwC Auditor
TipRanks · 06/18 20:41
Heartflow shareholders approve PwC as auditor for fiscal 2026
PUBT · 06/18 20:11
Weekly Report: what happened at HTFL last week (0608-0612)?
Weekly Report · 06/15 09:00
Heartflow CEO John C.M. Farquhar disposes of 22,562 common shares worth $642,017
PUBT · 06/12 22:56
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)
TipRanks · 06/11 11:21
Weekly Report: what happened at HTFL last week (0601-0605)?
Weekly Report · 06/08 09:00
Baron Discovery Fund Q1 2026: Who Moved The Needle
Seeking Alpha · 06/08 05:35
SaaS-Pocalypse
Seeking Alpha · 06/08 04:55
Weekly Report: what happened at HTFL last week (0525-0529)?
Weekly Report · 06/01 09:00
Is HeartFlow Stock a Buy After an Institutional Investor Initiated a Position Worth $2.7 Million?
The Motley Fool · 05/31 06:02
Weekly Report: what happened at HTFL last week (0518-0522)?
Weekly Report · 05/25 09:00
Heartflow CMO Campbell Rogers disposes 9,219 shares worth $261,704.46
PUBT · 05/20 21:56
HeartFlow (HTFL) Valuation Check After Recent Share Price Volatility
Simply Wall St · 05/20 04:48
Weekly Report: what happened at HTFL last week (0511-0515)?
Weekly Report · 05/18 09:00
Companies Like HeartFlow (NASDAQ:HTFL) Are In A Position To Invest In Growth
Simply Wall St · 05/16 12:45
HeartFlow Is Maintained at Buy by Canaccord Genuity
Dow Jones · 05/15 18:53
HeartFlow Price Target Cut to $37.00/Share From $43.00 by Canaccord Genuity
Dow Jones · 05/15 18:53
Canaccord Genuity Maintains Buy on HeartFlow, Lowers Price Target to $37
Benzinga · 05/15 18:43
More
Webull provides a variety of real-time HTFL stock news. You can receive the latest news about HEARTFLOW INC through multiple platforms. This information may help you make smarter investment decisions.
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.